The lack of efficacy of SMARCA2/4 BRD inhibitors in SMARCA4-mutated cancers suggested the ATPase domain rather than the BRD as the therapeutically relevant target in oncology, which was confirmed by genetic complementation studies [105]. The gene discussed is DNAH8; the disease is cancer.